Technetium-99m-HMPAO brain SPECT in neonates with hypoglycemic encephalopathy.
Regional brain injury in three neonates with hypoglycemic encephalopathy are presented using serial 99mTc-hexamethyl propyleneamine oxime (HMPAO) SPECT and, for comparison, MRI. During the acute stage, both 99mTc-HMPAO SPECT and MRI reveal abnormalities in the posterior cerebrum. Technetium-99m-HMPAO SPECT reveals further areas of insult, for example the frontal lobes. The degree of hypoperfusion correlates with the clinical severity of hypoglycemia during the neonatal period and subsequent neurological sequelae. Follow-up with HMPAO SPECT several months after insult demonstrates persistent hypoperfusion in some areas, mainly in the occipital and posterior parietal regions. MRI can depict morphological changes with superior resolution. Because morphological change generally follows slowly after functional change, MRI is less sensitive than HMPAO SPECT in detecting and predicting the extent of hypoglycemic cerebral injury during the acute phase. HMPAO SPECT during the acute stage is a valuable tool for evaluating the extent and severity of brain injury in neonates with hypoglycemic encephalopathy.
Department of Nuclear Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
N T
NT
Chiu
C C
CC
Huang
Y C
YC
Chang
C H
CH
Lin
W J
WJ
Yao
C Y
CY
Yu
D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology; D001925:Brain Damage, Chronic / Q000000981:diagnostic imaging* / Q000473:pathology; D002560:Cerebrovascular Circulation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007003:Hypoglycemia / Q000000981:diagnostic imaging* / Q000473:pathology; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D008297:Male; D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon
D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime